Loading…
Loading…
Sartorius (OTCMKTS:SARTF - Get Free Report) and Integra LifeSciences (NASDAQ: IART - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership. Insider and Institutional Ownership 84.8% of Integra LifeSciences shares
Sartorius Aktiengesellschaft (SOAGY) Analyst/Investor Day Transcript
Sartorius Aktiengesellschaft (SOAGY) Q4 2025 Earnings Call Transcript
Sartorius (OTCMKTS:SARTF - Get Free Report) and ClearPoint Neuro (NASDAQ: CLPT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability. Earnings and Valuation This table compares Sartorius and ClearPoint
Sartorius AG (SARTF) is rebounding with strong bioprocess segment growth and improving profit margins, despite a challenging biopharma environment. Secular demand for biologics and increased manufacturing complexity drive long-term growth, supported by industry capex and geopolitical reshoring trends. SARTF's financials show revenue and EBITDA growth, but high leverage and potential dilution remain key risks for investors to monitor.
Bio-Rad Laboratories was a positive contributor after the company reported steadier earnings than the market expected. PVH also remains our largest share repurchaser for the year after buying a teens percentage of shares outstanding at great prices. Rayonier was an immediate contributor.
Sartorius Aktiengesellschaft (OTCPK:SOAGY) Q3 2025 Earnings Call October 16, 2025 7:00 AM EDT Company Participants Petra Muller - Head of Investor Relations Michael Grosse - CEO & Chairman of the Executive Board Florian Funck - CFO & Member of Executive Board Rene Faber - Head of Bioprocess Solutions Division & Member of Executive Board Alexandra Gatzemeyer - Head of the Lab Products & Services Division and Member of Executive Board Conference Call Participants Odysseas Manesiotis - BNP Paribas Exane, Research Division Zain Ebrahim - JPMorgan Chase & Co, Research Division Charles Pitman - Barclays Bank PLC, Research Division Charlie Haywood - BofA Securities, Research Division James Quigley - Goldman Sachs Group, Inc., Research Division Douglas Schenkel - Wolfe Research, LLC Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Charles Weston - RBC Capital Markets, Research Division Matthew Weston - UBS Investment Bank, Research Division Oliver Metzger - ODDO BHF Corporate & Markets, Research Division Thibault Boutherin - Morgan Stanley, Research Division Oliver Reinberg - Kepler Cheuvreux, Research Division Harry Gillis - Joh. Berenberg, Gossler & Co. KG, Research Division Edward Hall - Stifel, Nicolaus & Company, Incorporated, Research Division Delphine Le Louet - Sanford C.
Sartorius Aktiengesellschaft (OTCPK:SARTF) Q2 2025 Earnings Conference Call July 22, 2025 7:00 AM ET Company Participants Alexandra Gatzemeyer - Head of the Lab Products & Services Division and Member of Executive Board Florian Funck - CFO & Member of Executive Board Michael Grosse - CEO & Chairman of the Executive Board Rene Faber - Head of Bioprocess Solutions Division & Member of Executive Board Conference Call Participants Charles Pitman - Barclays Bank PLC, Research Division Charles Robert Weston - RBC Capital Markets, Research Division Charlie Haywood - BofA Securities, Research Division Delphine Le Louet - Sanford C. Bernstein & Co., LLC.
No recent filings indexed.